Immunotherapy for breast cancer: Current and future strategies

被引：31
作者：
Williams A.D. [1 ]
Payne K.K. [2 ]
Posey A.D., Jr. [4 ,5 ]
Hill C. [3 ]
Conejo-Garcia J. [3 ]
June C.H. [4 ,5 ]
Tchou J. [1 ]
机构：
[1] Department of Surgery, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Boulevard, 10th floor South, Philadelphia, 19104, PA
[2] The Wistar Institute, Philadelphia, PA
[3] Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
[4] Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
[5] Perelman School of Medicine, Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA
来源：
Current Surgery Reports | / 5卷 / 12期
关键词：
Breast cancer; Cancer vaccines; Chimeric antigen receptor T cells (CAR T); Immune checkpoint; Immunotherapy; Oncolytic viruses;
D O I：
10.1007/s40137-017-0194-1
中图分类号：
学科分类号：
摘要：
Purpose of Review The breast tumor microenvironment is immunosuppressive and is increasingly recognized to play a significant role in tumorigenesis. A deeper understanding of normal and aberrant interactions between malignant and immune cells has allowed researchers to harness the immune system with novel immunotherapy strategies, many of which have shown promise in breast cancer. This review discusses the application of immunotherapy to the treatment of breast cancer. Recent Findings Both basic science and clinical trial data are rapidly developing in the use of immunotherapy for breast cancer. The current clinical trial landscape includes therapeutic vaccines, immune checkpoint blockade, anti-bodies, cytokines, and adoptive cell therapy. Summary Despite early failures, the application of immunotherapeutic strategies to the treatment of breast cancer holds promise. © Springer Science+Business Media, LLC 2017.
引用
收藏
相关论文
共 94 条
[1]  
McCarthy E.F., The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas, Iowa Orthop J, 26, pp. 154-158, (2006)
[2]  
Rosenberg S.A., Spiess P., Lafreniere R., A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lym-phocytes, Science, 233, 4770, pp. 1318-1321, (1986)
[3]  
Hanahan D., Weinberg R.A., Hallmarks of cancer: The next generation, Cell, 144, 5, pp. 646-674, (2011)
[4]  
Couzin-Frankel J., Breakthrough of the year 2013, Cancer Immunother Sci, 342, 6165, pp. 1432-1433, (2013)
[5]  
Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 8, pp. 725-733, (2011)
[6]  
Leach D.R., Krummel M.F., Allison J.P., Enhancement of antitumor immunity by CTLA-4 blockade, Science, 271, 5256, pp. 1734-1736, (1996)
[7]  
Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., Akerley W., van den Eertwegh A.J., Lutzky J., Lorigan P., Vaubel J.M., Linette G.P., Hogg D., Ottensmeier C.H., Lebbe C., Peschel C., Quirt I., Clark J.I., Wolchok J.D., Weber J.S., Tian J., Yellin M.J., Nichol G.M., Hoos A., Urba W.J., Improved survival with ipili-mumab in patients with metastatic melanoma, N Engl J Med, 363, 8, pp. 711-723, (2010)
[8]  
Robert C., Ribas A., Wolchok J.D., Hodi F.S., Hamid O., Kefford R., Weber J.S., Joshua A.M., Hwu W.J., Gangadhar T.C., Patnaik A., Dronca R., Zarour H., Joseph R.W., Boasberg P., Chmielowski B., Mateus C., Postow M.A., Gergich K., Elassaiss-Schaap J., Li X.N., Iannone R., Ebbinghaus S.W., Kang S.P., Daud A., Anti-pro-grammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial, Lancet, 384, 9948, pp. 110
[9]  
Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., Redfern C.H., Ferrari A.C., Dreicer R., Sims R.B., Xu Y., Froh-Lich M.W., Schellhammer P.F., Investigators I.S., Sipuleucel-T immunotherapy for castration-resistant prostate cancer, N Engl J Med, 363, 5, pp. 411-422, (2010)
[10]  
Small E.J., Schellhammer P.F., Higano C.S., Redfern C.H., Nemu-Naitis J.J., Valone F.H., Verjee S.S., Jones L.A., Hershberg R.M., Pla-cebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymp-tomatic hormone refractory prostate cancer, J Clin Oncol, 24, 19, pp. 3089-3094, (2006)
12345678910